Vitrakvi

Vitrakvi (Larotrectinib) is an oral prescription therapy used for treating solid tumors with NTRK gene fusions. This targeted treatment helps manage cancer by blocking specific signals that drive tumor growth. Vitrakvi is available by prescription only.

Vitrakvi is prescribed to treat solid tumors that have a specific genetic change called an NTRK gene fusion. This includes certain types of lung, thyroid, and salivary gland cancers, as well as other solid tumors in adults and children. It is used when the cancer has spread or cannot be removed by surgery. People often ask, what is Larotrectinib used for, and the answer is solid tumors with NTRK fusions.

Vitrakvi works by targeting the NTRK gene fusion, which may help slow or stop the growth of cancer cells. Patients may experience a range of effects while taking this medication, including fatigue, nausea, or dizziness. Some individuals report improved symptoms as their condition is managed.

Vitrakvi should be taken exactly as prescribed by a healthcare provider. Patients should inform their doctor about all medications, supplements, and medical conditions before starting treatment. Regular monitoring may be required to check for side effects or changes in health status.

Larotrectinib may interact with other medications, including strong CYP3A inhibitors or inducers, which can affect how it works. Alcohol and certain foods may also influence its effects. Always discuss current medications with a healthcare provider to avoid potential interactions.